Online inquiry

IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15534MR)

This product GTTS-WQ15534MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TGM2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001323316.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7052
UniProt ID P21980
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15534MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15819MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ3281MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ2291MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ2053MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ1431MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ13353MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ15795MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ10427MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW